Despite the general consensus related to the high tumor cell internalization rate of agonists for optimal imaging and in vivo therapy [25], it has been recently shown that high-affinity somatostatin antagonists (both sst2- and sst3-selective analogs), despite their poor tumor cell internalization properties, can show clearer images and pharmacokinetic profiles [26]. Here, SST is linked to neoplasm.